Table 2.
Negative binomial generalized linear mixed-effects model of anti-S-Ab levels in untreated and treated MS patients (anti-N negative) 6 months after the second dose (T2) of BNT162b2 vaccine.
| DMTs | N | Median anti-S in U/ml (IQR 25-75) | IRR (IQR 25-75) | SE | p value |
|---|---|---|---|---|---|
| IFN | 53 | 735 (342.3-1137) | 1.08 (0.70-1.69) | 0.22 | 0.73 |
| DMF | 127 | 554 (299.75-1010.5) | 1.07 (0.73-1.57) | 0.19 | 0.71 |
| ALEM | 10 | 912 (845.1-1030.9) | 1.00 (0.48-2.34) | 0.39 | 0.99 |
| TER | 51 | 389 (242-875.15) | 1.00 (0.64-1.57) | 0.22 | 0.99 |
| GA | 39 | 489 (308.65-854.8) | 0.91 (0.57-1.48) | 0.24 | 0.69 |
| NAT | 50 | 564 (265.55-892.27) | 0.70 (0.43-1.15) | 0.24 | 0.14 |
| AZA | 20 | 382 (200.07-611.3) | 0.68 (0.38-1.27) | 0.30 | 0.19 |
| UNT | 71 | 357 (170.6-625.7) | Reference | – | – |
| FTY | 108 | 37 (4.55-115.77) | 0.17 (0.11-0.24) | 0.19 | 1.82E-21 |
| OCR | 79 | 9 (4-52.815) | 0.07 (0.04-0.10) | 0.20 | 4.54E-42 |
| RTX | 15 | 4 (4-16.63) | 0.06 (0.03-0.12) | 0.33 | 1.35E-17 |
DMT, disease modifying therapy; UNT, untreated; ALEM, alemtuzumab; IFN, interferon; GA, glatiramer acetate; DMF, dimethyl fumarate; NAT, natalizumab; CLA, cladribine; TER, teriflunomide; AZA, azathioprine; FTY, fingolimod; RTX, rituximab; OCR, ocrelizumab; MET, methotrexate; BTK, Bruton Tyrosine Kinase trial; IQR, interquartile range; SE, standard error; IRR, Incidence Rate Ratio calculated as exp(coefficient) (11). Bold value indicate the Reference sample.